Hikari Araki

TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models

A. Fujioka, Kimihiro Ito, R. Wadhwa, 2019, Molecular Cancer Therapeutics.

A semimechanistic population pharmacokinetic and pharmacodynamic model incorporating autoinduction for the dose justification of TAS‐114

I. Ieiri, T. Takenaka, K. Yoshisue, 2021, CPT: pharmacometrics & systems pharmacology.

TAS2940, a novel brain‐penetrable pan‐ERBB inhibitor, for tumors with HER2 and EGFR aberrations

S. Kobayashi, S. Mizuarai, S. Tsuji, 2022, Cancer science.